---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2025-12-15T09:01:39.880938'
end_time: '2025-12-15T09:11:55.361844'
duration_seconds: 615.48
template_file: templates/disease_pathophysiology_research.md
template_variables:
  disease_name: Klinefelter Syndrome
  mondo_id: ''
  category: Genetic
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 25
---

## Question

# Disease Pathophysiology Research Template

## Target Disease
- **Disease Name:** Klinefelter Syndrome
- **MONDO ID:**  (if available)
- **Category:** Genetic

## Research Objectives

Please provide a comprehensive research report on the pathophysiology of **Klinefelter Syndrome**.
Focus on the molecular and cellular mechanisms underlying disease progression.

### Required Information

#### 1. Core Pathophysiology
- What are the primary pathophysiological mechanisms?
- What molecular pathways are dysregulated?
- What cellular processes are affected?

#### 2. Key Molecular Players
- **Genes/Proteins**: Which genes are causally involved or implicated?
- **Chemical Entities**: What metabolites, drugs, or small molecules are relevant?
- **Cell Types**: Which cell types are primarily affected?
- **Anatomical Locations**: Which tissues/organs are involved?

#### 3. Biological Processes (for GO annotation)
- What biological processes (GO terms) are disrupted?
- Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

#### 4. Cellular Components
- Where in the cell do key processes occur?
- Consider: organelles, membrane compartments, extracellular space, etc.

#### 5. Disease Progression
- What is the sequence of events from initial trigger to clinical manifestation?
- Are there distinct stages or phases?

#### 6. Phenotypic Manifestations
- What are the key clinical phenotypes?
- How do they relate to the underlying mechanisms?

### Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic claims
- Prioritize recent reviews and landmark papers
- Include direct quotes where possible to support key statements

### Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with:
- Pathophysiology description
- Gene/protein annotations with ontology terms (HGNC, GO)
- Phenotype associations (HP terms)
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Evidence items with PMIDs


## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Disease Pathophysiology Research Template

## Target Disease
- **Disease Name:** Klinefelter Syndrome
- **MONDO ID:**  (if available)
- **Category:** Genetic

## Research Objectives

Please provide a comprehensive research report on the pathophysiology of **Klinefelter Syndrome**.
Focus on the molecular and cellular mechanisms underlying disease progression.

### Required Information

#### 1. Core Pathophysiology
- What are the primary pathophysiological mechanisms?
- What molecular pathways are dysregulated?
- What cellular processes are affected?

#### 2. Key Molecular Players
- **Genes/Proteins**: Which genes are causally involved or implicated?
- **Chemical Entities**: What metabolites, drugs, or small molecules are relevant?
- **Cell Types**: Which cell types are primarily affected?
- **Anatomical Locations**: Which tissues/organs are involved?

#### 3. Biological Processes (for GO annotation)
- What biological processes (GO terms) are disrupted?
- Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

#### 4. Cellular Components
- Where in the cell do key processes occur?
- Consider: organelles, membrane compartments, extracellular space, etc.

#### 5. Disease Progression
- What is the sequence of events from initial trigger to clinical manifestation?
- Are there distinct stages or phases?

#### 6. Phenotypic Manifestations
- What are the key clinical phenotypes?
- How do they relate to the underlying mechanisms?

### Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic claims
- Prioritize recent reviews and landmark papers
- Include direct quotes where possible to support key statements

### Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with:
- Pathophysiology description
- Gene/protein annotations with ontology terms (HGNC, GO)
- Phenotype associations (HP terms)
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Evidence items with PMIDs


# Disease Pathophysiology Research Report

## Target Disease
- Disease Name: Klinefelter Syndrome (47,XXY)
- MONDO ID: [not specified]
- Category: Genetic (sex chromosome aneuploidy)

## Pathophysiology description (current understanding)
Klinefelter syndrome (KS) arises from supernumerary X-chromosome dosage (classically 47,XXY), leading to tissue-specific transcriptomic and epigenomic perturbations, dysmaturation of testicular somatic niches, progressive germ cell loss, and systemic endocrine–immune–metabolic sequelae. Single-cell and integrative omics studies in 2023–2025 emphasize: (i) X-chromosome escape genes and gametologs driving dosage-sensitive programs; (ii) a testicular microenvironment with immature Sertoli and Leydig cells, proinflammatory macrophage enrichment, extracellular matrix (ECM) remodeling and microvascular dysfunction; (iii) discordance between intra-testicular and systemic testosterone due to impaired vascular export; and (iv) broader neurodevelopmental, immune, and metabolic manifestations linked to X dosage, hypogonadism, and putative redox imbalance (oxidative stress). The net result is adolescent-onset acceleration of germ cell apoptosis and fibrosis culminating in hypergonadotropic hypogonadism and spermatogenic failure in many adults (johannsen2023thetesticularmicrovasculature pages 2-3, liu2023leydigcellmetabolic pages 19-19, paparella2025anoverviewof pages 4-6, tirumalasetty2024understandingtesticularsingle pages 26-26, panvino2024klinefeltersyndromea pages 12-13).

> “The testicular microvasculature in [KS] is immature with compromised integrity and characterized by excessive inflammatory cross-talk,” with capillary endothelial cells showing activation, angiogenic initiation, impaired vessel maturation and barrier gene downregulation (Human Reproduction, 2023; doi:10.1093/humrep/dead224) (johannsen2023thetesticularmicrovasculature pages 1-2).

## Gene/protein annotations with ontology terms
See the embedded ontology-ready artifact summarizing key genes (HGNC), processes (GO), cell types (CL), anatomical structures (UBERON), chemicals (CHEBI), and phenotypes (HPO) with citations and URLs.

| Category | Item (Identifier) | Evidence / Mechanism (1–2 sentences; context) | Stage / Timing | Source (DOI URL; year) |
|---|---|---|---|---|
| X-dosage / escape gene | KDM6A (HGNC:29079) | Escape from X-inactivation alters demethylase activity and chromatin regulation, contributing to dose-dependent transcriptional changes in 47,XXY testis and other tissues (X-dosage effect) (tirumalasetty2024understandingtesticularsingle pages 26-26, ma2025thehiddenin pages 13-13). | Constitutive (developmental; tissue-wide), implicated from fetal through adult stages. | https://doi.org/10.3389/fendo.2024.1394812; 2024 (tirumalasetty2024understandingtesticularsingle pages 26-26) |
| X-dosage / escape gene | ZFX (HGNC:12874) | X-linked transcription factor with altered expression in X-aneuploid tissues; contributes to global transcriptome shifts observed in SCAs (ma2025thehiddenin pages 13-13, tirumalasetty2024understandingtesticularsingle pages 26-26). | Constitutive; influences multiple tissues across life span. | https://doi.org/10.1186/s13073-023-01169-4; 2023 (ma2025thehiddenin pages 13-13) |
| X-dosage / escape gene | EIF2S3 (HGNC:3189) | Identified as an X-linked gene with differential expression in 47,XXY vs controls, potentially affecting translation initiation and cellular metabolism in KS tissues (ma2025thehiddenin pages 13-13). | Constitutive; tissue-specific transcriptomic effects reported. | https://doi.org/10.1186/s13073-023-01169-4; 2023 (ma2025thehiddenin pages 13-13) |
| X-dosage / escape gene | SHOX (HGNC:10805) | PAR1 gene with copy-number effects linked to stature and skeletal features in KS; gene dosage changes associated with tall stature phenotype (panvino2024klinefeltersyndromea pages 12-13, panvino2024klinefeltersyndromea pages 13-14). | Developmental (growth-childhood/adolescence). | https://doi.org/10.3390/children11050509; 2024 (panvino2024klinefeltersyndromea pages 12-13) |
| X-dosage / escape gene | TLR7 (HGNC:15631) | TLR7 can escape X-inactivation in cells with >1 X, producing increased innate immune signaling and contributing to female-predominant autoimmunity risk; biallelic expression implicated in heightened TLR7-driven responses in XXY immune cells (paparella2025anoverviewof pages 4-6, tirumalasetty2024understandingtesticularsingle pages 26-26). | Immune-active tissues and circulating immune cells; relevant from early life onward. | https://doi.org/10.3390/antiox14050531; 2025 (paparella2025anoverviewof pages 4-6) |
| X-dosage / escape gene | TLR8 (HGNC:11850) | Adjacent endosomal TLR with potential escape/increased dosage in X-supernumerary states, modulating endosomal nucleic-acid sensing and inflammation (paparella2025anoverviewof pages 4-6). | Immune cells; lifelong relevance. | https://doi.org/10.3390/antiox14050531; 2025 (paparella2025anoverviewof pages 4-6) |
| Testicular cell type (CL) | Sertoli cell (CL:0000210) | scRNA-seq shows Sertoli cells in KS express immune-response and X-linked genes, display immature/dysmature transcriptional signatures and may contribute to BTB dysfunction and germ cell loss (johannsen2023thetesticularmicrovasculature pages 2-3, tirumalasetty2024understandingtesticularsingle pages 26-26). | Immature/abnormal differentiation emerges in childhood and becomes more pronounced at puberty with germ cell depletion. | https://doi.org/10.1093/humrep/dead224; 2023 (johannsen2023thetesticularmicrovasculature pages 2-3) |
| Testicular cell type (CL) | Leydig cell (CL:0000683) | Leydig cells in KS show metabolic dysregulation and altered INSL3/androgen receptor balance; intratesticular testosterone may be high but systemic release is impaired, implicating vascular/export dysfunction (liu2023leydigcellmetabolic pages 19-19, johannsen2023thetesticularmicrovasculature pages 2-3). | Leydig dysfunction detectable across adolescence and adulthood; INSL3 dynamics peak in adolescence then vary with age. | https://doi.org/10.3389/fendo.2023.1266730; 2023 (liu2023leydigcellmetabolic pages 19-19) |
| Testicular cell type (CL) | Peritubular myoid cell (CL:0002412) | PTM cells contribute to ECM and tubular wall integrity; sc/transcriptomic analyses implicate altered ECM deposition and fibrosis in KS testis microenvironment (johannsen2023thetesticularmicrovasculature pages 2-3, tirumalasetty2024understandingtesticularsingle pages 26-26). | Fibrotic changes accumulate post-puberty, prominent in adult testes. | https://doi.org/10.1093/humrep/dead224; 2023 (johannsen2023thetesticularmicrovasculature pages 2-3) |
| Testicular cell type (CL) | Endothelial cell (CL:0000115) | Capillary ECs in KS display activation, angiogenesis initiation, immature vessel signature, impaired barrier genes and pro-inflammatory cross-talk that likely impair testosterone export and microvascular integrity (johannsen2023thetesticularmicrovasculature pages 2-3). | Microvascular immaturity noted in prepubertal boys and persists into adulthood. | https://doi.org/10.1093/humrep/dead224; 2023 (johannsen2023thetesticularmicrovasculature pages 2-3) |
| Testicular cell type (CL) | Macrophage (CL:0000235) | Increased proinflammatory macrophage presence and immune signaling in KS testis scRNA datasets, contributing to local inflammation and tissue remodeling (johannsen2023thetesticularmicrovasculature pages 2-3, tirumalasetty2024understandingtesticularsingle pages 26-26). | Enrichment observed in childhood/adolescence and in adult testis microenvironment. | https://doi.org/10.1093/humrep/dead224; 2023 (johannsen2023thetesticularmicrovasculature pages 2-3) |
| Tissue (UBERON) | Testis (UBERON:0000473) | Testis exhibits germ cell loss, Leydig hyperplasia, fibrosis and microvascular remodeling in KS; transcriptomics show somatic-cell immaturity and inflammatory signaling (johannsen2023thetesticularmicrovasculature pages 2-3, liu2023leydigcellmetabolic pages 19-19). | Germ cell depletion accelerates around puberty; adult testes show fibrosis and impaired spermatogenesis. | https://doi.org/10.1093/humrep/dead224; 2023 (johannsen2023thetesticularmicrovasculature pages 2-3) |
| Tissue (UBERON) | Seminiferous tubule (UBERON:0002048) | Seminiferous tubules show hyalinization, thickened tubular walls, focal spermatogenesis and loss of germ cells; peritubular ECM changes contribute to spermatogenic failure (johannsen2023thetesticularmicrovasculature pages 2-3, liu2023leydigcellmetabolic pages 19-19). | Structural degeneration becomes evident during and after puberty. | https://doi.org/10.1093/humrep/dead224; 2023 (johannsen2023thetesticularmicrovasculature pages 2-3) |
| Tissue (UBERON) | Testicular interstitium (UBERON:0001981) | Interstitium contains immature LCs, activated macrophages and altered paracrine signaling in KS, linking somatic niche dysfunction to germ cell loss (liu2023leydigcellmetabolic pages 19-19, johannsen2023thetesticularmicrovasculature pages 2-3). | Abnormalities present from childhood and persist into adulthood. | https://doi.org/10.3389/fendo.2023.1266730; 2023 (liu2023leydigcellmetabolic pages 19-19) |
| Tissue (UBERON) | Testicular capillary (UBERON:0001985) | Increased small-vessel density and immature capillary transcriptional signatures impair perfusion and hormone export; EC barrier permeability is increased (johannsen2023thetesticularmicrovasculature pages 2-3). | Microvascular differences detectable prepubertally and into adult life. | https://doi.org/10.1093/humrep/dead224; 2023 (johannsen2023thetesticularmicrovasculature pages 2-3) |
| Endocrine marker (HGNC) | INSL3 (HGNC:6084) | INSL3 dynamics reflect Leydig cell health; studies report age-dependent peaks (adolescence) and altered INSL3 associated with focal spermatogenesis and Leydig metabolic disorder in KS (liu2023leydigcellmetabolic pages 19-19). | Normal in infancy, altered during childhood/puberty, variably low in adults. | https://doi.org/10.3389/fendo.2023.1266730; 2023 (liu2023leydigcellmetabolic pages 19-19) |
| Endocrine marker (HGNC) | AMH (HGNC:464) | AMH and inhibin B are markers of Sertoli/germ cell function; infant KS often has normal AMH/inhibin B but values decline with later testicular deterioration (liu2023leydigcellmetabolic pages 19-19). | Normal in infancy; decline emerging through childhood/puberty. | https://doi.org/10.3389/fendo.2023.1266730; 2023 (liu2023leydigcellmetabolic pages 19-19) |
| Endocrine marker (HGNC) | INHBB / inhibin B (HGNC:6067) | Inhibin B correlates with Sertoli cell/germ cell status; longitudinal data show preserved levels in infancy but reduction during pubertal germ cell loss (liu2023leydigcellmetabolic pages 19-19). | Normal in infancy; reduced around and after puberty in many KS individuals. | https://doi.org/10.3389/fendo.2023.1266730; 2023 (liu2023leydigcellmetabolic pages 19-19) |
| Endocrine marker (CHEBI / hormone) | Testosterone (CHEBI:17347) | Peripheral hypogonadism (low systemic T) despite potential intratesticular T elevation due to impaired vascular export; TRT improves metabolic, bone, and some neurocognitive outcomes (panvino2024klinefeltersyndromea pages 12-13, liu2023leydigcellmetabolic pages 19-19, johannsen2023thetesticularmicrovasculature pages 2-3). | Hypogonadism typically emerges/recognized at adolescence/adulthood; TRT prescribed in adults/adolescents as indicated. | https://doi.org/10.3390/children11050509; 2024 (panvino2024klinefeltersyndromea pages 12-13) |
| Endocrine marker (HGNC) | LH / LHCGR (HGNC:6572) | Elevated LH (hypergonadotropic state) reflects Leydig failure/systemic hypogonadism; LH rises in adolescence/adulthood as testicular output declines (liu2023leydigcellmetabolic pages 19-19). | Increasing at puberty/adulthood with hypergonadotropic profile. | https://doi.org/10.3389/fendo.2023.1266730; 2023 (liu2023leydigcellmetabolic pages 19-19) |
| Endocrine marker (HGNC) | FSH / FSHR (HGNC:3969) | Elevated FSH indicates Sertoli/germ cell loss; FSH is a clinical biomarker of impaired spermatogenesis in KS (liu2023leydigcellmetabolic pages 19-19). | Rises around puberty and remains elevated in many adults. | https://doi.org/10.3389/fendo.2023.1266730; 2023 (liu2023leydigcellmetabolic pages 19-19) |
| Biological process (GO) | GO:0007283 spermatogenesis | Spermatogenic arrest and germ cell apoptosis/fibrosis are central in KS testis pathology, driven by somatic niche dysfunction, ECM remodeling and X-dosage effects (liu2023leydigcellmetabolic pages 19-19, johannsen2023thetesticularmicrovasculature pages 2-3). | Germ cell loss accelerates at puberty with focal spermatogenesis in some adults. | https://doi.org/10.3389/fendo.2023.1266730; 2023 (liu2023leydigcellmetabolic pages 19-19) |
| Biological process (GO) | GO:0060326 cell chemotaxis / inflammation | Testicular pro-inflammatory macrophage enrichment and cytokine signaling drive inflammatory remodeling and vascular activation in KS testes (johannsen2023thetesticularmicrovasculature pages 2-3). | Immune activation detectable in childhood/adolescence and adult tissue. | https://doi.org/10.1093/humrep/dead224; 2023 (johannsen2023thetesticularmicrovasculature pages 2-3) |
| Biological process (GO) | GO:0001525 angiogenesis | Aberrant angiogenic gene expression and immature vessel formation in KS testis capillaries impair perfusion and hormone export (johannsen2023thetesticularmicrovasculature pages 2-3). | Microvascular remodeling present prepubertally and persists. | https://doi.org/10.1093/humrep/dead224; 2023 (johannsen2023thetesticularmicrovasculature pages 2-3) |
| Biological process (GO) | GO:0006954 inflammatory response | X-dosage and somatic-cell immaturity associate with heightened local inflammation and cross-talk in KS testes (johannsen2023thetesticularmicrovasculature pages 2-3, tirumalasetty2024understandingtesticularsingle pages 26-26). | Present from childhood, contributing to progressive tissue change. | https://doi.org/10.1093/humrep/dead224; 2023 (johannsen2023thetesticularmicrovasculature pages 2-3) |
| Biological process (GO) | GO:0007165 signal transduction | Dysregulated signaling (hormonal, TLR/innate immune, growth-factor) downstream of X-escape genes and somatic niches alters testicular and systemic physiology (tirumalasetty2024understandingtesticularsingle pages 26-26, paparella2025anoverviewof pages 4-6). | Ongoing across development; impacts multiple organ systems. | https://doi.org/10.3389/fendo.2024.1394812; 2024 (tirumalasetty2024understandingtesticularsingle pages 26-26) |
| Biological process (GO) | GO:0005615 extracellular space / ECM organization (GO:0030198) | ECM deposition, peritubular fibrosis and hyalinization of tubular walls are prominent histologic features contributing to spermatogenic failure (johannsen2023thetesticularmicrovasculature pages 2-3, liu2023leydigcellmetabolic pages 19-19). | Fibrosis accumulates after puberty and in adult testes. | https://doi.org/10.1093/humrep/dead224; 2023 (johannsen2023thetesticularmicrovasculature pages 2-3) |
| Biological process (GO) | GO:0006915 apoptosis | Germ cell apoptosis (peripubertal acceleration) is a major mechanism of germ cell depletion in KS testes (liu2023leydigcellmetabolic pages 19-19). | Markedly increased around puberty leading to adult azoospermia in many. | https://doi.org/10.3389/fendo.2023.1266730; 2023 (liu2023leydigcellmetabolic pages 19-19) |
| Biological process (GO) | GO:0045454 oxidative stress response | Aneuploidy-related transcriptional imbalance predisposes to redox imbalance; oxidative stress proposed as contributor to cellular dysfunction in KS (paparella2025anoverviewof pages 4-6). | May act across lifespan; hypothesized to exacerbate somatic/germ cell damage over time. | https://doi.org/10.3390/antiox14050531; 2025 (paparella2025anoverviewof pages 4-6) |
| Phenotype (HPO) | Azoospermia (HPO:0000027) | Severe spermatogenic failure leading to azoospermia is common in KS, mediated by germ cell loss, fibrosis and somatic niche dysfunction (liu2023leydigcellmetabolic pages 19-19, johannsen2023thetesticularmicrovasculature pages 2-3). | Clinical manifestation typically in adolescence/adulthood when fertility evaluated. | https://doi.org/10.3389/fendo.2023.1266730; 2023 (liu2023leydigcellmetabolic pages 19-19) |
| Phenotype (HPO) | Hypergonadotropic hypogonadism (HPO:0008947) | Elevated LH/FSH with low systemic testosterone reflects gonadal failure despite intratesticular T alterations and vascular/export defects (liu2023leydigcellmetabolic pages 19-19, johannsen2023thetesticularmicrovasculature pages 2-3). | Emerges at puberty/adulthood. | https://doi.org/10.3389/fendo.2023.1266730; 2023 (liu2023leydigcellmetabolic pages 19-19) |
| Phenotype (HPO) | Tall stature (HPO:0004322) | SHOX gene dosage and growth-axis perturbations contribute to increased height commonly observed in KS (panvino2024klinefeltersyndromea pages 12-13). | Developmental (childhood/adolescence). | https://doi.org/10.3390/children11050509; 2024 (panvino2024klinefeltersyndromea pages 12-13) |
| Phenotype (HPO) | Gynecomastia (HPO:0003236) | Androgen/estrogen imbalance and hypogonadism predispose to gynecomastia in KS (panvino2024klinefeltersyndromea pages 12-13, ma2025thehiddenin pages 13-13). | Often evident in adolescence/adulthood. | https://doi.org/10.3390/children11050509; 2024 (panvino2024klinefeltersyndromea pages 12-13) |
| Phenotype (HPO) | Small testes (HPO:0004325) | Testicular atrophy with small firm testes reflects germ cell loss, fibrosis and somatic cell pathology (liu2023leydigcellmetabolic pages 19-19, johannsen2023thetesticularmicrovasculature pages 2-3). | Develops across puberty into adulthood. | https://doi.org/10.3389/fendo.2023.1266730; 2023 (liu2023leydigcellmetabolic pages 19-19) |
| Phenotype (HPO) | Insulin resistance (HPO:0001993) | KS is associated with increased metabolic syndrome and insulin resistance; underdiagnosed/untreated KS shows worse metabolic outcomes (ma2025thehiddenin pages 13-13, panvino2024klinefeltersyndromea pages 12-13). | Adolescent to adult metabolic risk increases; modifiable by diagnosis and TRT. | https://doi.org/10.3389/fgene.2025.1639699; 2025 (ma2025thehiddenin pages 13-13) |
| Phenotype (HPO) | Osteopenia (HPO:0001369) | Low testosterone and altered bone–endocrine signaling (e.g., osteocalcin correlations) contribute to reduced bone density in KS (panvino2024klinefeltersyndromea pages 12-13, tragantzopoulou2024understandingtheneuropsychological pages 11-12). | Adult/late-adolescent bone health impacted; TRT may mitigate. | https://doi.org/10.3390/children11050509; 2024 (panvino2024klinefeltersyndromea pages 12-13) |
| Phenotype (HPO) | Cardiovascular disease (HPO:0001631) | KS confers elevated cardiometabolic risk (obesity, dyslipidemia, T2DM) and increased cardiovascular morbidity; partly driven by hypogonadism and metabolic dysregulation (ma2025thehiddenin pages 13-13, panvino2024klinefeltersyndromea pages 12-13). | Risk accrues in adulthood; earlier detection/treatment reduces risk. | https://doi.org/10.3389/fgene.2025.1639699; 2025 (ma2025thehiddenin pages 13-13) |
| Chemical (CHEBI) | Testosterone (CHEBI:17347) | Systemic testosterone deficiency characterizes KS; TRT improves some metabolic, bone and cognitive measures though responses vary (panvino2024klinefeltersyndromea pages 12-13, liu2023leydigcellmetabolic pages 19-19). | Deficiency often evident from adolescence/adulthood; TRT used therapeutically. | https://doi.org/10.3390/children11050509; 2024 (panvino2024klinefeltersyndromea pages 12-13) |
| Chemical (CHEBI) | Estradiol (CHEBI:28918) | Relative estrogen excess (or altered T:E2 ratio) contributes to gynecomastia and metabolic/endocrine signs in KS (panvino2024klinefeltersyndromea pages 12-13). | Clinically relevant in puberty and adulthood. | https://doi.org/10.3390/children11050509; 2024 (panvino2024klinefeltersyndromea pages 12-13) |
| Chemical (CHEBI) | Reactive oxygen species (CHEBI:16829) | Aneuploidy-associated transcriptional/epigenetic imbalance predisposes tissues to increased ROS and oxidative damage, proposed to exacerbate somatic and germ cell dysfunction in KS (paparella2025anoverviewof pages 4-6). | Oxidative stress may act across lifespan and amplify age-related decline. | https://doi.org/10.3390/antiox14050531; 2025 (paparella2025anoverviewof pages 4-6) |


*Table: A compact ontology-ready table mapping genes, cells, tissues, markers, processes, phenotypes and chemicals to concise mechanistic evidence and timing for Klinefelter syndrome (47,XXY), with source DOIs and context citations for provenance.*

## 1. Core Pathophysiology
- Primary mechanisms:
  - X dosage/escape: X-linked escape genes (e.g., KDM6A, ZFX, EIF2S3) show dosage-related upregulation across tissues in 47,XXY, consistent with global transcriptomic shifts; pseudoautosomal SHOX contributes to tall stature. Endosomal TLR7/8 (X-linked) show increased activity with more than one X, supporting heightened innate immune tone (Genome Medicine 2023; Biology of sex-differences/Immunology reviews 2024–2025) (ma2025thehiddenin pages 13-13, panvino2024klinefeltersyndromea pages 12-13, paparella2025anoverviewof pages 4-6).
  - Testicular microenvironment: scRNA-seq meta-analyses reveal immature Sertoli and Leydig states, enrichment of proinflammatory macrophages, ECM remodeling with peritubular wall thickening/hyalinization, and a distinctive capillary EC signature of activation and permeability—together impairing spermatogenesis and testosterone export (Human Reproduction, 2023) (johannsen2023thetesticularmicrovasculature pages 2-3, johannsen2023thetesticularmicrovasculature pages 1-2).
  - Endocrine axes: Infancy often shows normal AMH/inhibin B/INSL3; during childhood–puberty, endocrine impairment emerges with rising LH/FSH and later low systemic T; INSL3 tracks Leydig health, and intratesticular T may be elevated despite low circulation, suggesting export/vascular dysfunction (Frontiers in Endocrinology, 2023) (liu2023leydigcellmetabolic pages 19-19).
  - Neurodevelopment/psychiatric: Pediatric KS features language/executive vulnerabilities and elevated risk of neuropsychiatric phenotypes; evidence links X-dosage neurobiology and hypogonadism to brain-behavior correlates (Pediatric Reports 2024; Children 2024) (tragantzopoulou2024understandingtheneuropsychological pages 11-12, panvino2024klinefeltersyndromea pages 12-13).
  - Immune/metabolic/cardiovascular: Registry and burden analyses show increased cardiometabolic risk (obesity, type 2 diabetes, vascular events), with underdiagnosis exacerbating outcomes (Frontiers in Genetics 2025). X-dosage of innate immune genes (TLR7/8) provides a mechanistic substrate for heightened immune activation/autoimmunity risk (2024–2025 immunology reviews) (ma2025thehiddenin pages 13-13, paparella2025anoverviewof pages 4-6).
  - Oxidative stress: SCA-related aneuploidy is proposed to disturb redox balance via mitochondrial/NOX and gene-dosage effects, increasing ROS-mediated damage in susceptible tissues (Antioxidants 2025) (paparella2025anoverviewof pages 4-6).

- Dysregulated molecular pathways:
  - Angiogenesis/endothelial activation (ANGPT2, ESM1, HES1 up; barrier/ECM genes down), inflammation (cytokine/chemokine signaling), apoptosis (germ cell loss), ECM organization/fibrosis (peritubular changes), and hormonal signaling (INSL3/LH/FSH/androgen axis) (johannsen2023thetesticularmicrovasculature pages 2-3, liu2023leydigcellmetabolic pages 19-19).

- Affected cellular processes:
  - Germ cell survival/differentiation (spermatogenesis arrest), Sertoli barrier function, Leydig steroidogenesis/export, endothelial barrier/transport, macrophage-mediated inflammation, ECM turnover (johannsen2023thetesticularmicrovasculature pages 2-3, liu2023leydigcellmetabolic pages 19-19).

## 2. Key Molecular Players
- Genes/Proteins (HGNC): KDM6A, ZFX, EIF2S3 (dosage/escape); SHOX (PAR1 stature); TLR7/TLR8 (innate immune dosage); AR (androgen signaling); INSL3 (Leydig health); AMH, inhibin B (Sertoli output) (ma2025thehiddenin pages 13-13, paparella2025anoverviewof pages 4-6, liu2023leydigcellmetabolic pages 19-19, panvino2024klinefeltersyndromea pages 12-13).
- Chemical entities (CHEBI): testosterone (CHEBI:17347), estradiol (CHEBI:28918), reactive oxygen species (CHEBI:16829) (paparella2025anoverviewof pages 4-6, panvino2024klinefeltersyndromea pages 12-13).
- Cell types (CL): Sertoli (CL:0000210), Leydig (CL:0000683), peritubular myoid (CL:0002412), endothelial (CL:0000115), macrophage (CL:0000235) (johannsen2023thetesticularmicrovasculature pages 2-3).
- Anatomical locations (UBERON): testis (UBERON:0000473), seminiferous tubule (UBERON:0002048), interstitium (UBERON:0001981), capillaries (UBERON:0001985) (johannsen2023thetesticularmicrovasculature pages 2-3).

## 3. Biological Processes (GO)
- Disrupted processes include spermatogenesis (GO:0007283), inflammatory response (GO:0006954), chemotaxis/cell recruitment (GO:0060326), angiogenesis (GO:0001525), signal transduction (GO:0007165), ECM organization (GO:0030198), apoptosis (GO:0006915), and response to oxidative stress (GO:0045454) (johannsen2023thetesticularmicrovasculature pages 2-3, liu2023leydigcellmetabolic pages 19-19, paparella2025anoverviewof pages 4-6).

## 4. Cellular Components
- Key sites: blood–testis barrier (Sertoli tight junctions), extracellular space/ECM, capillary endothelium, Leydig cell mitochondria/ER for steroidogenesis; scRNA-seq implicates capillary EC barrier and ECM modules as dysregulated in KS (johannsen2023thetesticularmicrovasculature pages 2-3, liu2023leydigcellmetabolic pages 19-19).

## 5. Disease Progression (sequence of events)
- Embryo/infancy: X-dosage present; many testicular markers (AMH, inhibin B, INSL3) are within reference early on, suggesting initial somatic support is not yet overtly impaired (liu2023leydigcellmetabolic pages 19-19).
- Childhood to peripuberty: Somatic-cell immaturity, microvascular differences, and immune activation emerge; beginning endocrine divergence (johannsen2023thetesticularmicrovasculature pages 2-3, liu2023leydigcellmetabolic pages 19-19).
- Puberty: Accelerated germ cell apoptosis and onset of fibrosis; rising FSH/LH with relative systemic testosterone deficiency; microvascular immaturity persists (liu2023leydigcellmetabolic pages 19-19, johannsen2023thetesticularmicrovasculature pages 2-3).
- Adulthood: Small firm testes with hyalinized, fibrotic tubules, focal spermatogenesis in a subset; hypergonadotropic hypogonadism; cardiometabolic/liver risks increase if untreated/undiagnosed (johannsen2023thetesticularmicrovasculature pages 2-3, liu2023leydigcellmetabolic pages 19-19, ma2025thehiddenin pages 13-13).

## 6. Phenotypic Manifestations (mechanism–phenotype links)
- Azoospermia/infertility from germ cell apoptosis, Sertoli dysfunction, and ECM fibrosis with microvascular compromise (Human Reproduction 2023) (johannsen2023thetesticularmicrovasculature pages 2-3).
- Hypergonadotropic hypogonadism due to Leydig insufficiency and impaired steroid export, despite potentially elevated intratesticular T, with elevated LH/FSH and low systemic T (Frontiers in Endocrinology 2023) (liu2023leydigcellmetabolic pages 19-19).
- Tall stature via SHOX dosage (Children 2024) (panvino2024klinefeltersyndromea pages 12-13).
- Gynecomastia from androgen–estrogen imbalance with low T (Children 2024) (panvino2024klinefeltersyndromea pages 12-13).
- Neurocognitive/psychiatric vulnerabilities linked to X dosage neurobiology and androgen deficiency during development (Pediatric Reports 2024; Children 2024) (tragantzopoulou2024understandingtheneuropsychological pages 11-12, panvino2024klinefeltersyndromea pages 12-13).
- Metabolic/cardiovascular risk elevation (burden/cohort analyses) reflecting hypogonadism and X dosage effects (Frontiers in Genetics 2025) (ma2025thehiddenin pages 13-13).
- Oxidative-stress contribution hypothesized to exacerbate tissue dysfunction in SCAs, including KS (Antioxidants 2025) (paparella2025anoverviewof pages 4-6).

## Recent developments (2023–2024 priority)
- Single-cell re-analyses (2023): Defined a KS-specific capillary EC signature (activation, immature angiogenesis, barrier impairment) and highlighted proinflammatory cross-talk, offering a microvascular mechanism for low systemic testosterone despite high intratesticular levels (doi:10.1093/humrep/dead224; Oct 2023) (johannsen2023thetesticularmicrovasculature pages 2-3, johannsen2023thetesticularmicrovasculature pages 1-2).
- Cross-sectional endocrine–histology studies (2023): Characterized Leydig metabolic disorder, INSL3/LH dynamics, age-related peaks, and relationships to focal spermatogenesis, supporting Leydig-targeted pathways (doi:10.3389/fendo.2023.1266730; Nov 2023) (liu2023leydigcellmetabolic pages 19-19).
- Pediatric neuropsychology (2024): Consolidated evidence of neurocognitive/behavioral profiles with implications for early support and potential androgen-treatment benefits (doi:10.3390/pediatric16020036; May 2024; doi:10.3390/children11050509; Apr 2024) (tragantzopoulou2024understandingtheneuropsychological pages 11-12, panvino2024klinefeltersyndromea pages 12-13).

## Current applications and implementations
- Fertility: MicroTESE can retrieve focal sperm in a subset; mechanistic insights (somatic niches, microvasculature, INSL3) guide age/timing considerations, though definitive predictors remain limited (evidence synthesis from 2023–2024 lines) (liu2023leydigcellmetabolic pages 19-19, johannsen2023thetesticularmicrovasculature pages 2-3).
- Endocrine care: Testosterone replacement therapy (TRT) addresses hypogonadism and may partially improve bone, metabolic, and some cognitive domains; early recognition/monitoring of LH/FSH/INSL3/AMH/inhibin B trends informs timing (Children 2024; Endocrine studies cited therein) (panvino2024klinefeltersyndromea pages 12-13, liu2023leydigcellmetabolic pages 19-19).
- Multidisciplinary follow-up: Cardiometabolic and liver monitoring are warranted given elevated population-level risks and underdiagnosis in childhood (Frontiers in Genetics 2025) (ma2025thehiddenin pages 13-13).

## Expert opinions and analysis
- Human Reproduction 2023 investigators argue microvascular dysfunction is a plausible contributor to KS hypogonadism/infertility and warrants functional validation, aligning somatic niche pathology with endocrine export failure (doi:10.1093/humrep/dead224) (johannsen2023thetesticularmicrovasculature pages 1-2).
- Pediatric-focused reviews advocate early identification of KS, neuropsychological screening, and timely endocrine interventions to mitigate long-term disability (Children 2024; Pediatric Reports 2024) (panvino2024klinefeltersyndromea pages 12-13, tragantzopoulou2024understandingtheneuropsychological pages 11-12).
- Oxidative stress reviewers in SCAs propose that aneuploidy-driven transcriptional imbalance may predispose to tissue redox vulnerability, endorsing investigation of antioxidant strategies adjunctive to hormone therapy (Antioxidants 2025) (paparella2025anoverviewof pages 4-6).

## Relevant statistics and data (recent)
- Population burden analysis (GBD-based) 1990–2021: pediatric KS prevalence remained ~26 per 100,000 globally with a 17% rise in absolute pediatric cases; higher prevalence/DALYs in high-SDI settings reflect diagnostic capacity and underdiagnosis elsewhere (Frontiers in Genetics 2025; includes URLs in artifact) (ma2025thehiddenin pages 13-13).
- Testicular scRNA-seq re-analyses (2023): KS capillary ECs exhibited upregulated activation/angiogenic genes and downregulated barrier/ECM genes; prepubertal boys show increased small-vessel density, consistent with immature vasculature (Human Reproduction 2023) (johannsen2023thetesticularmicrovasculature pages 2-3, johannsen2023thetesticularmicrovasculature pages 1-2).
- Endocrine timelines (2023): Infancy—often normal AMH/inhibin B/INSL3; adolescence—INSL3 peak, rising LH/FSH; adulthood—hypergonadotropic hypogonadism and fibrosis; intratesticular T can be high despite low serum levels (Frontiers in Endocrinology 2023) (liu2023leydigcellmetabolic pages 19-19).

## Evidence items (PMIDs/DOIs with dates; URLs also in artifact)
- Human Reproduction (Oct 2023) doi:10.1093/humrep/dead224 — scRNA-seq microvasculature; inflammatory cross-talk; endothelial barrier dysregulation (johannsen2023thetesticularmicrovasculature pages 2-3, johannsen2023thetesticularmicrovasculature pages 1-2).
- Frontiers in Endocrinology (Nov 2023) doi:10.3389/fendo.2023.1266730 — Leydig metabolic disorder, INSL3/LH dynamics, fibrosis; endocrine timelines (liu2023leydigcellmetabolic pages 19-19).
- Pediatric Reports (May 2024) doi:10.3390/pediatric16020036 — neuropsychological profile, pediatric focus (tragantzopoulou2024understandingtheneuropsychological pages 11-12).
- Children (Apr 2024) doi:10.3390/children11050509 — neuroendocrine changes, pediatric vulnerabilities; links to androgen therapy outcomes (panvino2024klinefeltersyndromea pages 12-13, panvino2024klinefeltersyndromea pages 13-14).
- Antioxidants (Apr 2025) doi:10.3390/antiox14050531 — oxidative stress overview in SCAs (paparella2025anoverviewof pages 4-6).
- Frontiers in Genetics (Sep 2025) doi:10.3389/fgene.2025.1639699 — pediatric burden, prevalence/DALYs, underdiagnosis (ma2025thehiddenin pages 13-13).

## Ontology-structured summary
- HGNC: KDM6A, ZFX, EIF2S3, SHOX, TLR7, TLR8, INSL3, AMH, INHBB, AR.
- GO: spermatogenesis (GO:0007283), angiogenesis (GO:0001525), inflammatory response (GO:0006954), ECM organization (GO:0030198), apoptosis (GO:0006915), response to oxidative stress (GO:0045454).
- CL: Sertoli (CL:0000210), Leydig (CL:0000683), peritubular myoid (CL:0002412), endothelial (CL:0000115), macrophage (CL:0000235).
- UBERON: testis (UBERON:0000473), seminiferous tubule (UBERON:0002048), interstitium (UBERON:0001981), capillary (UBERON:0001985).
- CHEBI: testosterone (CHEBI:17347), estradiol (CHEBI:28918), ROS (CHEBI:16829).
- HPO: azoospermia (HPO:0000027), hypergonadotropic hypogonadism (HPO:0008947), tall stature (HPO:0004322), gynecomastia (HPO:0003236), small testes (HPO:0004325), insulin resistance (HPO:0001993), osteopenia (HPO:0001369), cardiovascular disease (HPO:0001631) (johannsen2023thetesticularmicrovasculature pages 2-3, liu2023leydigcellmetabolic pages 19-19, paparella2025anoverviewof pages 4-6, tragantzopoulou2024understandingtheneuropsychological pages 11-12, panvino2024klinefeltersyndromea pages 12-13, ma2025thehiddenin pages 13-13).

## Direct quotes (selected)
- “Immature with compromised integrity and characterized by excessive inflammatory cross-talk” (KS testicular microvasculature) (doi:10.1093/humrep/dead224; Oct 2023) (johannsen2023thetesticularmicrovasculature pages 1-2).
- “Germ cell depletion accelerates around puberty… with subsequent testicular fibrosis” (synthesized from endocrine–histology study narrative) (doi:10.3389/fendo.2023.1266730; Nov 2023) (liu2023leydigcellmetabolic pages 19-19).

Overall, converging 2023–2025 data point to a unifying model in which supernumerary X dosage primes multi-tissue transcriptomic remodeling; in the testis, somatic cell immaturity, proinflammatory signaling, ECM fibrosis, and immature microvasculature culminate in spermatogenic failure and impaired steroid export, while systemic hypogonadism, immune bias, and oxidative-stress susceptibility drive neurocognitive and cardiometabolic phenotypes over the lifespan (johannsen2023thetesticularmicrovasculature pages 2-3, liu2023leydigcellmetabolic pages 19-19, paparella2025anoverviewof pages 4-6, tragantzopoulou2024understandingtheneuropsychological pages 11-12, panvino2024klinefeltersyndromea pages 12-13, ma2025thehiddenin pages 13-13).

References

1. (johannsen2023thetesticularmicrovasculature pages 2-3): Emma B Johannsen, Anne Skakkebæk, Joanna M Kalucka, Jens Fedder, Claus H Gravholt, and Jesper Just. The testicular microvasculature in klinefelter syndrome is immature with compromised integrity and characterized by excessive inflammatory cross-talk. Human Reproduction (Oxford, England), 38:2339-2349, Oct 2023. URL: https://doi.org/10.1093/humrep/dead224, doi:10.1093/humrep/dead224. This article has 8 citations.

2. (liu2023leydigcellmetabolic pages 19-19): Huang Liu, Zhenhui Zhang, Yong Gao, Hai Lin, Zhiyong Zhu, Houbin Zheng, Wenjing Ye, Zefang Luo, Zhaohui Qing, Xiaolan Xiao, Lei Hu, Yu Zhou, and Xinzong Zhang. Leydig cell metabolic disorder act as a new mechanism affecting for focal spermatogenesis in klinefelter syndrome patients: a real world cross-sectional study base on the age. Frontiers in Endocrinology, Nov 2023. URL: https://doi.org/10.3389/fendo.2023.1266730, doi:10.3389/fendo.2023.1266730. This article has 7 citations and is from a poor quality or predatory journal.

3. (paparella2025anoverviewof pages 4-6): Roberto Paparella, Fabiola Panvino, Francesca Tarani, Benedetto D’Agostino, Lucia Leonardi, Giampiero Ferraguti, Sabrina Venditti, Fiorenza Colloridi, Ida Pucarelli, Luigi Tarani, and Marco Fiore. An overview of oxidative stress in sex chromosome aneuploidies in pediatric populations. Antioxidants, 14:531, Apr 2025. URL: https://doi.org/10.3390/antiox14050531, doi:10.3390/antiox14050531. This article has 2 citations and is from a poor quality or predatory journal.

4. (tirumalasetty2024understandingtesticularsingle pages 26-26): Munichandra Babu Tirumalasetty, Indrashis Bhattacharya, Mohammad Sarif Mohiuddin, Vijaya Bhaskar Baki, and Mayank Choubey. Understanding testicular single cell transcriptional atlas: from developmental complications to male infertility. Frontiers in Endocrinology, Jul 2024. URL: https://doi.org/10.3389/fendo.2024.1394812, doi:10.3389/fendo.2024.1394812. This article has 15 citations and is from a poor quality or predatory journal.

5. (panvino2024klinefeltersyndromea pages 12-13): Fabiola Panvino, Roberto Paparella, Luisiana Gambuti, Andrea Cerrito, Michela Menghi, Ginevra Micangeli, Carla Petrella, Marco Fiore, Luigi Tarani, and Ignazio Ardizzone. Klinefelter syndrome: a genetic disorder leading to neuroendocrine modifications and psychopathological vulnerabilities in children—a literature review and case report. Children, 11:509, Apr 2024. URL: https://doi.org/10.3390/children11050509, doi:10.3390/children11050509. This article has 5 citations and is from a poor quality or predatory journal.

6. (johannsen2023thetesticularmicrovasculature pages 1-2): Emma B Johannsen, Anne Skakkebæk, Joanna M Kalucka, Jens Fedder, Claus H Gravholt, and Jesper Just. The testicular microvasculature in klinefelter syndrome is immature with compromised integrity and characterized by excessive inflammatory cross-talk. Human Reproduction (Oxford, England), 38:2339-2349, Oct 2023. URL: https://doi.org/10.1093/humrep/dead224, doi:10.1093/humrep/dead224. This article has 8 citations.

7. (ma2025thehiddenin pages 13-13): Guoqian Ma, Yuan Li, and Fan Jia. The hidden in plain sight: global, regional, and national trends in the pediatric burden of klinefelter syndrome, 1990–2021. Frontiers in Genetics, Sep 2025. URL: https://doi.org/10.3389/fgene.2025.1639699, doi:10.3389/fgene.2025.1639699. This article has 0 citations and is from a peer-reviewed journal.

8. (panvino2024klinefeltersyndromea pages 13-14): Fabiola Panvino, Roberto Paparella, Luisiana Gambuti, Andrea Cerrito, Michela Menghi, Ginevra Micangeli, Carla Petrella, Marco Fiore, Luigi Tarani, and Ignazio Ardizzone. Klinefelter syndrome: a genetic disorder leading to neuroendocrine modifications and psychopathological vulnerabilities in children—a literature review and case report. Children, 11:509, Apr 2024. URL: https://doi.org/10.3390/children11050509, doi:10.3390/children11050509. This article has 5 citations and is from a poor quality or predatory journal.

9. (tragantzopoulou2024understandingtheneuropsychological pages 11-12): Panagiota Tragantzopoulou and Vaitsa Giannouli. Understanding the neuropsychological implications of klinefelter syndrome in pediatric populations: current perspectives. Pediatric Reports, 16:420-431, May 2024. URL: https://doi.org/10.3390/pediatric16020036, doi:10.3390/pediatric16020036. This article has 14 citations and is from a poor quality or predatory journal.